161 related articles for article (PubMed ID: 25010341)
1. Insights into the interactions between maleimide derivates and GSK3β combining molecular docking and QSAR.
Quesada-Romero L; Mena-Ulecia K; Tiznado W; Caballero J
PLoS One; 2014; 9(7):e102212. PubMed ID: 25010341
[TBL] [Abstract][Full Text] [Related]
2. Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.
Quesada-Romero L; Caballero J
Mol Divers; 2014 Feb; 18(1):149-59. PubMed ID: 24081608
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.
Prasanna S; Daga PR; Xie A; Doerksen RJ
J Comput Aided Mol Des; 2009 Feb; 23(2):113-27. PubMed ID: 18839067
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
Akhtar M; Bharatam PV
Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
[TBL] [Abstract][Full Text] [Related]
5. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.
Kim KH; Gaisina I; Gallier F; Holzle D; Blond SY; Mesecar A; Kozikowski AP
J Mol Model; 2009 Dec; 15(12):1463-79. PubMed ID: 19440740
[TBL] [Abstract][Full Text] [Related]
6. Binding studies and quantitative structure-activity relationship of 3-amino-1H-indazoles as inhibitors of GSK3β.
Caballero J; Zilocchi S; Tiznado W; Collina S; Rossi D
Chem Biol Drug Des; 2011 Oct; 78(4):631-41. PubMed ID: 21756288
[TBL] [Abstract][Full Text] [Related]
7. Monte Carlo method based QSAR modeling of maleimide derivatives as glycogen synthase kinase-3β inhibitors.
Živković JV; Trutić NV; Veselinović JB; Nikolić GM; Veselinović AM
Comput Biol Med; 2015 Sep; 64():276-82. PubMed ID: 26257010
[TBL] [Abstract][Full Text] [Related]
8. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
9. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids as CDK1 Inhibitors: Insights in Their Binding Orientations and Structure-Activity Relationship.
Navarro-Retamal C; Caballero J
PLoS One; 2016; 11(8):e0161111. PubMed ID: 27517610
[TBL] [Abstract][Full Text] [Related]
11. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
13. 3D QSAR for GSK-3beta inhibition by indirubin analogues.
Zhang N; Jiang Y; Zou J; Zhang B; Jin H; Wang Y; Yu Q
Eur J Med Chem; 2006 Mar; 41(3):373-8. PubMed ID: 16442187
[TBL] [Abstract][Full Text] [Related]
14. Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides.
Sivaprakasam P; Xie A; Doerksen RJ
Bioorg Med Chem; 2006 Dec; 14(24):8210-8. PubMed ID: 17010615
[TBL] [Abstract][Full Text] [Related]
15. Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors.
Balupuri A; Balasubramanian PK; Gadhe CG; Cho SJ
SAR QSAR Environ Res; 2014; 25(8):651-71. PubMed ID: 24911214
[TBL] [Abstract][Full Text] [Related]
16. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
17. PLS and shape-based similarity analysis of maleimides--GSK-3 inhibitors.
Crisan L; Pacureanu L; Avram S; Bora A; Avram S; Kurunczi L
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):599-610. PubMed ID: 24047148
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structural insight of a highly selective protein kinase inhibitor hit through click chemistry.
Gu G; Wang H; Liu P; Fu C; Li Z; Cao X; Li Y; Fang Q; Xu F; Shen J; Wang PG
Chem Commun (Camb); 2012 Mar; 48(22):2788-90. PubMed ID: 22314408
[TBL] [Abstract][Full Text] [Related]
19. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
20. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.
Zheng J; Kong H; Wilson JM; Guo J; Chang Y; Yang M; Xiao G; Sun P
PLoS One; 2014; 9(4):e93704. PubMed ID: 24722522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
